These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 18464021

  • 1. First human exposure to exogenous single-dose oral estetrol in early postmenopausal women.
    Visser M, Holinka CF, Coelingh Bennink HJ.
    Climacteric; 2008; 11 Suppl 1():31-40. PubMed ID: 18464021
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics and systemic endocrine effects of the phyto-oestrogen 8-prenylnaringenin after single oral doses to postmenopausal women.
    Rad M, Hümpel M, Schaefer O, Schoemaker RC, Schleuning WD, Cohen AF, Burggraaf J.
    Br J Clin Pharmacol; 2006 Sep; 62(3):288-96. PubMed ID: 16934044
    [Abstract] [Full Text] [Related]

  • 3. Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis model.
    Coelingh Bennink HJ, Heegaard AM, Visser M, Holinka CF, Christiansen C.
    Climacteric; 2008 Sep; 11 Suppl 1():2-14. PubMed ID: 18464016
    [Abstract] [Full Text] [Related]

  • 4. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women.
    Ruckle J, Jacobs M, Kramer W, Pearsall AE, Kumar R, Underwood KW, Seehra J, Yang Y, Condon CH, Sherman ML.
    J Bone Miner Res; 2009 Apr; 24(4):744-52. PubMed ID: 19049340
    [Abstract] [Full Text] [Related]

  • 5. Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverelix in healthy men--a first-dose-in-humans study.
    Erb K, Pechstein B, Schueler A, Engel J, Hermann R.
    Clin Pharmacol Ther; 2000 Jun; 67(6):660-9. PubMed ID: 10872648
    [Abstract] [Full Text] [Related]

  • 6. Safety, tolerability, and pharmacokinetics of TAS-108 in normal healthy post-menopausal female subjects: a phase I study on single oral dose.
    Yamaya H, Yoshida K, Kuritani J, Yonezawa J, Tsuda M, Shindo T, Nagayama S, Buzdar AU.
    J Clin Pharm Ther; 2005 Oct; 30(5):459-70. PubMed ID: 16164493
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
    Lim KS, Kim JR, Choi YJ, Shin KH, Kim KP, Hong JH, Cho JY, Shin HS, Yu KS, Shin SG, Kwon OH, Hwang DM, Kim JA, Jang IJ.
    Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
    [Abstract] [Full Text] [Related]

  • 8. Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors.
    Lockhart AC, Bukowski R, Rothenberg ML, Wang KK, Cooper W, Grover J, Appleman L, Mayer PR, Shapiro M, Zhu AX.
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):203-9. PubMed ID: 17091249
    [Abstract] [Full Text] [Related]

  • 9. Single oral dose safety, tolerability, and pharmacokinetics of PNU-96391 in healthy volunteers.
    Rodríguez CA, Azie NE, Adams G, Donaldson K, Francom SF, Staton BA, Bombardt PA.
    J Clin Pharmacol; 2004 Mar; 44(3):276-83. PubMed ID: 14973308
    [Abstract] [Full Text] [Related]

  • 10. The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of CH4987655 in healthy volunteers: target suppression using a biomarker.
    Lee L, Niu H, Rueger R, Igawa Y, Deutsch J, Ishii N, Mu S, Sakamoto Y, Busse-Reid R, Gimmi C, Goelzer P, De Schepper S, Yoshimura Y, Barrett J, Ishikawa Y, Weissgerber G, Peck R.
    Clin Cancer Res; 2009 Dec 01; 15(23):7368-74. PubMed ID: 19934286
    [Abstract] [Full Text] [Related]

  • 11. Suppression of serum luteinizing hormone in postmenopausal women by an orally administered nonpeptide antagonist of the gonadotropin-releasing hormone receptor (NBI-42902).
    Struthers RS, Chen T, Campbell B, Jimenez R, Pan H, Yen SS, Bozigian HP.
    J Clin Endocrinol Metab; 2006 Oct 01; 91(10):3903-7. PubMed ID: 16849403
    [Abstract] [Full Text] [Related]

  • 12. A pharmacokinetic comparison of single doses of once-daily cyclobenzaprine extended-release 15 mg and 30 mg: a randomized, double-blind, two-period crossover study in healthy volunteers.
    Darwish M, Chang S, Hellriegel ET.
    Clin Ther; 2009 Jan 01; 31(1):108-14. PubMed ID: 19243711
    [Abstract] [Full Text] [Related]

  • 13. Randomized, crossover, single-blind, placebo-controlled, human pharmacology clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: multiple-dose pharmacokinetics.
    Algorta J, Pena MA, Alvarez A, Maraschiello C, Maruhn D, Windisch M, Mucke HA.
    Int J Clin Pharmacol Ther; 2009 Jul 01; 47(7):483-90. PubMed ID: 19640356
    [Abstract] [Full Text] [Related]

  • 14. Effects of clomiphene and raloxifene on gonadotrophin secretion in postmenopausal women: evidence of nongenomic action.
    Garas A, Trypsianis G, Kallitsaris A, Milingos S, Messinis IE.
    Clin Endocrinol (Oxf); 2004 Aug 01; 61(2):256-62. PubMed ID: 15272923
    [Abstract] [Full Text] [Related]

  • 15. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone.
    Dunbar JL, Turncliff RZ, Dong Q, Silverman BL, Ehrich EW, Lasseter KC.
    Alcohol Clin Exp Res; 2006 Mar 01; 30(3):480-90. PubMed ID: 16499489
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics and pharmacodynamics of the ETA-selective endothelin receptor antagonist SPP301 in healthy human subjects.
    Dieterle W, Mann J, Kutz K.
    J Clin Pharmacol; 2004 Jan 01; 44(1):59-66. PubMed ID: 14681342
    [Abstract] [Full Text] [Related]

  • 17. Ghrelin agonist (TZP-101): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study.
    Lasseter KC, Shaughnessy L, Cummings D, Pezzullo JC, Wargin W, Gagnon R, Oliva J, Kosutic G.
    J Clin Pharmacol; 2008 Feb 01; 48(2):193-202. PubMed ID: 18199894
    [Abstract] [Full Text] [Related]

  • 18. The pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of NN703, a novel orally active growth hormone secretagogue in healthy male volunteers.
    Zdravkovic M, Søgaard B, Ynddal L, Christiansen T, Agersø H, Thomsen MS, Falch JE, Ilondo MM.
    Growth Horm IGF Res; 2000 Aug 01; 10(4):193-8. PubMed ID: 11032702
    [Abstract] [Full Text] [Related]

  • 19. The pharmacokinetics, pharmacodynamics, safety and tolerability following 7 days daily oral treatment with NN703 in healthy male subjects.
    Zdravkovic M, Christiansen T, Eliot L, Agersoe H, Thomsen MS, Falch JF, Søgaard B, Ynddal L, Ilondo MM.
    Growth Horm IGF Res; 2001 Feb 01; 11(1):41-8. PubMed ID: 11437473
    [Abstract] [Full Text] [Related]

  • 20. Safety, tolerability, and single- and multiple-dose pharmacokinetics of piperaquine phosphate in healthy subjects.
    Ahmed T, Sharma P, Gautam A, Varshney B, Kothari M, Ganguly S, Moehrle JJ, Paliwal J, Saha N, Batra V.
    J Clin Pharmacol; 2008 Feb 01; 48(2):166-75. PubMed ID: 18199893
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.